CDXS - Codexis Inc Stock Price, Fair Value and News

3.69USD+0.04 (+1.10%)Market Closed

Market Summary

USD3.69+0.04

Market Closed

1.10%

CDXS Stock Price

View Fullscreen

CDXS RSI Chart

CDXS Valuation

Market Cap

260.4M

Price/Earnings (Trailing)

-4

Price/Sales (Trailing)

3.51

EV/EBITDA

-3.87

Price/Free Cashflow

-4.8

CDXS Price/Sales (Trailing)

CDXS Profitability

EBT Margin

-87.65%

Return on Equity

-82.16%

Return on Assets

-43.55%

Free Cashflow Yield

-20.83%

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

74.2M

Rev. Growth (Yr)

31.51%

Rev. Growth (Qtr)

-35.72%

CDXS Earnings

Earnings (TTM)

-65.1M

Earnings Growth (Yr)

49.13%

Earnings Growth (Qtr)

-59.97%

Breaking Down CDXS Revenue

Last 7 days

3.9%

Last 30 days

16.0%

Last 90 days

38.7%

Trailing 12 Months

6.3%

How does CDXS drawdown profile look like?

CDXS Financial Health

Current Ratio

3.71

Debt/Equity

0.35

Debt/Cashflow

-1.82

CDXS Investor Care

Shares Dilution (1Y)

5.68%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	74.2M	0	0	0
2023	116.2M	99.1M	74.0M	70.1M
2022	122.1M	135.0M	132.7M	138.6M
2021	72.4M	82.9M	101.3M	104.8M
2020	67.5M	70.2M	66.7M	69.1M
2019	62.1M	60.9M	65.9M	68.5M
2018	56.1M	59.3M	66.2M	60.6M
2017	48.8M	43.2M	38.3M	50.0M
2016	43.0M	53.0M	50.5M	48.8M
2015	35.0M	34.5M	44.4M	41.8M
2014	27.5M	27.1M	30.6M	35.3M
2013	68.6M	52.7M	30.3M	31.9M
2012	124.0M	120.8M	113.9M	88.3M
2011	112.4M	114.0M	120.2M	123.9M
2010	0	91.0M	99.0M	107.1M
2009	0	0	0	82.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with NestlÃƒÆ’Ã‚Â© Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CEO	Dr. Stephen George Dilly MBBS, Ph.D.
WEBSITE	codexis.com
INDUSTRY	Biotechnology
EMPLOYEES	248

Codexis Inc Frequently Asked Questions

What is the ticker symbol for Codexis Inc? What does CDXS stand for in stocks?

CDXS is the stock ticker symbol of Codexis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Codexis Inc (CDXS)?

As of Fri Jul 26 2024, market cap of Codexis Inc is 260.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXS stock?

You can check CDXS's fair value in chart for subscribers.

Is Codexis Inc a good stock to buy?

The fair value guage provides a quick view whether CDXS is over valued or under valued. Whether Codexis Inc is cheap or expensive depends on the assumptions which impact Codexis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXS.

What is Codexis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CDXS's PE ratio (Price to Earnings) is -4 and Price to Sales (PS) ratio is 3.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Codexis Inc's stock?

In the past 10 years, Codexis Inc has provided 0.066 (multiply by 100 for percentage) rate of return.